- Home
- LPSN vs ADVM Comparison
LPSN vs ADVM Comparison
Compare LPSN & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPSN
- ADVM
- Stock Information
- Founded
- LPSN 1995
- ADVM 2006
- Country
- LPSN United States
- ADVM United States
- Employees
- LPSN N/A
- ADVM N/A
- Industry
- LPSN EDP Services
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LPSN Technology
- ADVM Health Care
- Exchange
- LPSN Nasdaq
- ADVM Nasdaq
- Market Cap
- LPSN 84.5M
- ADVM 94.6M
- IPO Year
- LPSN 2000
- ADVM 2014
- Fundamental
- Price
- LPSN $6.31
- ADVM $4.30
- Analyst Decision
- LPSN Hold
- ADVM Buy
- Analyst Count
- LPSN 1
- ADVM 5
- Target Price
- LPSN N/A
- ADVM $16.60
- AVG Volume (30 Days)
- LPSN 410.9K
- ADVM 991.1K
- Earning Date
- LPSN 11-10-2025
- ADVM 11-07-2025
- Dividend Yield
- LPSN N/A
- ADVM N/A
- EPS Growth
- LPSN N/A
- ADVM N/A
- EPS
- LPSN N/A
- ADVM N/A
- Revenue
- LPSN $271,750,000.00
- ADVM $1,000,000.00
- Revenue This Year
- LPSN N/A
- ADVM $1,449.40
- Revenue Next Year
- LPSN N/A
- ADVM N/A
- P/E Ratio
- LPSN N/A
- ADVM N/A
- Revenue Growth
- LPSN N/A
- ADVM N/A
- 52 Week Low
- LPSN $5.44
- ADVM $1.78
- 52 Week High
- LPSN $31.20
- ADVM $8.18
- Technical
- Relative Strength Index (RSI)
- LPSN 71.16
- ADVM 50.39
- Support Level
- LPSN $5.81
- ADVM $3.98
- Resistance Level
- LPSN $7.16
- ADVM $4.34
- Average True Range (ATR)
- LPSN 0.60
- ADVM 0.31
- MACD
- LPSN -0.03
- ADVM -0.07
- Stochastic Oscillator
- LPSN 50.73
- ADVM 38.55
About LPSN LivePerson Inc.
LivePerson Inc is the enterprise leader in digital customer conversation. The Conversational Cloud, the Company's enterprise-class digital customer conversation platform, is trusted by the world's top brands to accelerate their contact center transformation, orchestrate conversations across all channels, departments, and systems, increase agent productivity, and deliver more personalized, AI-empowered customer experiences. The company has a presence in the United Kingdom, Asia-Pacific, Latin America, and Europe.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.